KYMR
Price
$40.61
Change
+$0.32 (+0.79%)
Updated
Jan 17 closing price
Capitalization
2.63B
33 days until earnings call
XENE
Price
$38.52
Change
-$1.10 (-2.78%)
Updated
Jan 17 closing price
Capitalization
2.94B
39 days until earnings call
Ad is loading...

KYMR vs XENE

Header iconKYMR vs XENE Comparison
Open Charts KYMR vs XENEBanner chart's image
Kymera Therapeutics
Price$40.61
Change+$0.32 (+0.79%)
Volume$343.66K
Capitalization2.63B
Xenon Pharmaceuticals
Price$38.52
Change-$1.10 (-2.78%)
Volume$469.48K
Capitalization2.94B
KYMR vs XENE Comparison Chart
Loading...
KYMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KYMR vs. XENE commentary
Jan 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KYMR is a Hold and XENE is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 18, 2025
Stock price -- (KYMR: $40.61 vs. XENE: $38.52)
Brand notoriety: KYMR and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KYMR: 68% vs. XENE: 114%
Market capitalization -- KYMR: $2.63B vs. XENE: $2.94B
KYMR [@Biotechnology] is valued at $2.63B. XENE’s [@Biotechnology] market capitalization is $2.94B. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KYMR’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 2 green FA rating(s).

  • KYMR’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 2 green, 3 red.
According to our system of comparison, XENE is a better buy in the long-term than KYMR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KYMR’s TA Score shows that 3 TA indicator(s) are bullish while XENE’s TA Score has 4 bullish TA indicator(s).

  • KYMR’s TA Score: 3 bullish, 3 bearish.
  • XENE’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, XENE is a better buy in the short-term than KYMR.

Price Growth

KYMR (@Biotechnology) experienced а +6.39% price change this week, while XENE (@Biotechnology) price change was +0.29% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

KYMR is expected to report earnings on May 01, 2025.

XENE is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($2.94B) has a higher market cap than KYMR($2.63B). KYMR YTD gains are higher at: 0.945 vs. XENE (-1.735). KYMR has higher annual earnings (EBITDA): -160.96M vs. XENE (-252.74M). XENE has more cash in the bank: 654M vs. KYMR (550M). XENE has less debt than KYMR: XENE (9.79M) vs KYMR (88.2M). KYMR has higher revenues than XENE: KYMR (87.6M) vs XENE (0).
KYMRXENEKYMR / XENE
Capitalization2.63B2.94B90%
EBITDA-160.96M-252.74M64%
Gain YTD0.945-1.735-54%
P/E RatioN/AN/A-
Revenue87.6M0-
Total Cash550M654M84%
Total Debt88.2M9.79M901%
FUNDAMENTALS RATINGS
XENE: Fundamental Ratings
XENE
OUTLOOK RATING
1..100
6
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
PROFIT vs RISK RATING
1..100
17
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
75
P/E GROWTH RATING
1..100
5
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
KYMRXENE
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 11 days ago
84%
Bullish Trend 11 days ago
79%
Momentum
ODDS (%)
Bearish Trend 11 days ago
85%
Bullish Trend 11 days ago
80%
MACD
ODDS (%)
Bullish Trend 11 days ago
76%
Bullish Trend 11 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 11 days ago
81%
Bullish Trend 11 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 11 days ago
87%
Bearish Trend 11 days ago
76%
Advances
ODDS (%)
Bullish Trend 16 days ago
85%
Bullish Trend 12 days ago
78%
Declines
ODDS (%)
Bearish Trend 20 days ago
88%
Bearish Trend 20 days ago
75%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 11 days ago
84%
Bearish Trend 11 days ago
78%
View a ticker or compare two or three
Ad is loading...
KYMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OANGX33.150.24
+0.73%
Oakmark Global Institutional
BVEFX20.330.14
+0.69%
Becker Value Equity Retail
VSEMX240.811.61
+0.67%
Vanguard Extended Market Index Instl Sel
TRHBX24.270.10
+0.41%
Nuveen Small Cap Blend Idx I
RRSRX28.82-0.01
-0.03%
Russell Inv Global Real Estate Secs R6

KYMR and

Correlation & Price change

A.I.dvisor indicates that over the last year, KYMR has been loosely correlated with CCCC. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if KYMR jumps, then CCCC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KYMR
1D Price
Change %
KYMR100%
+0.79%
CCCC - KYMR
60%
Loosely correlated
+2.07%
XENE - KYMR
50%
Loosely correlated
-2.78%
ERAS - KYMR
49%
Loosely correlated
-0.54%
ACLX - KYMR
48%
Loosely correlated
-0.79%
CRSP - KYMR
48%
Loosely correlated
+0.57%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with CRNX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
-2.78%
CRNX - XENE
47%
Loosely correlated
+2.38%
KYMR - XENE
46%
Loosely correlated
+0.79%
RCKT - XENE
44%
Loosely correlated
+0.98%
PLRX - XENE
44%
Loosely correlated
-3.36%
AURA - XENE
43%
Loosely correlated
+1.30%
More